TY - JOUR
T1 - Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters
AU - Shiels, Meredith S.
AU - Cole, Stephen R.
AU - Wegner, Scott
AU - Armenian, Haroutune
AU - Chmiel, Joan S.
AU - Anesan, Anuradha
AU - Marconi, Vincent C.
AU - Martinez-Maza, Otoniel
AU - Martinson, Jeremy
AU - Weintrob, Amy
AU - Jacobson, Lisa P.
AU - Crum-Cianflone, Nancy F.
PY - 2008/8/1
Y1 - 2008/8/1
N2 - OBJECTIVE:: To explore the impact of highly active antiretroviral therapy (HAART) on the prevention of AIDS-defining cancers relative to other AIDS-defining events. DESIGN:: Prospective cohort study using 2121 HIV+ male seroconverters (median age: 28 years, 51% white/non-Hispanic) in the Tri-Service AIDS Clinical Consortium (n = 1694) and the Multicenter AIDS Cohort Study (n = 427). METHODS:: Poisson regression models, with calendar periods to represent antiretroviral therapy, were extended to analyze first incident AIDS-defining cancers and other first AIDS-defining events as competing risks. RESULTS:: Eighty-one AIDS-defining cancers (64 Kaposi sarcomas; 17 non-Hodgkin lymphomas) and 343 other AIDS events occurred during 14,483 person-years in 1990-2006. The rate ratio of AIDS-defining cancers during the HAART calendar period was 0.26 (95% confidence limits: 0.15, 0.46) and of other AIDS-defining events was 0.28 (95% confidence limits: 0.21, 0.36) compared with the monotherapy/combination therapy calendar period, adjusting for age, infection duration, race, and cohort. The association of HAART with decreased AIDS incidence seemed to be equal (interaction ratio = 0.95 (95% confidence limits: 0.51, 1.74) for AIDS-defining cancers and other AIDS-defining events. CONCLUSIONS:: In human immunodeficiency virus-infected men, HAART seems equally protective against first AIDS-defining cancers and other first AIDS-defining events.
AB - OBJECTIVE:: To explore the impact of highly active antiretroviral therapy (HAART) on the prevention of AIDS-defining cancers relative to other AIDS-defining events. DESIGN:: Prospective cohort study using 2121 HIV+ male seroconverters (median age: 28 years, 51% white/non-Hispanic) in the Tri-Service AIDS Clinical Consortium (n = 1694) and the Multicenter AIDS Cohort Study (n = 427). METHODS:: Poisson regression models, with calendar periods to represent antiretroviral therapy, were extended to analyze first incident AIDS-defining cancers and other first AIDS-defining events as competing risks. RESULTS:: Eighty-one AIDS-defining cancers (64 Kaposi sarcomas; 17 non-Hodgkin lymphomas) and 343 other AIDS events occurred during 14,483 person-years in 1990-2006. The rate ratio of AIDS-defining cancers during the HAART calendar period was 0.26 (95% confidence limits: 0.15, 0.46) and of other AIDS-defining events was 0.28 (95% confidence limits: 0.21, 0.36) compared with the monotherapy/combination therapy calendar period, adjusting for age, infection duration, race, and cohort. The association of HAART with decreased AIDS incidence seemed to be equal (interaction ratio = 0.95 (95% confidence limits: 0.51, 1.74) for AIDS-defining cancers and other AIDS-defining events. CONCLUSIONS:: In human immunodeficiency virus-infected men, HAART seems equally protective against first AIDS-defining cancers and other first AIDS-defining events.
KW - AIDS-associated lymphoma
KW - Cancers
KW - Epidemiology
KW - Highly active antiretroviral therapy
KW - Kaposi sarcoma
KW - Opportunistic nfections
UR - http://www.scopus.com/inward/record.url?scp=50649114254&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50649114254&partnerID=8YFLogxK
U2 - 10.1097/QAI.0b013e31817dc42b
DO - 10.1097/QAI.0b013e31817dc42b
M3 - Article
C2 - 18614916
AN - SCOPUS:50649114254
SN - 1525-4135
VL - 48
SP - 485
EP - 490
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
IS - 4
ER -